Activities of L-glycyl-L-valine and L-glycyl-L-leucine dipeptidase were studied in the mucosa of the small intestine of rats following intraperitoneal administration of vinblastine sulfate (1.0 mg/kg). Activities of these dipeptidases were depressed significantly; the effect was maximal between 4 and 5 h after the injection and lasted for more than 16 h. The depression in the enzyme activities reached even up to 95% when the alkaloid was administered repeatedly in 4-hourly intervals. The present results, showing a dose-dependent inhibitory effect on these dipeptidases, suggest a toxic effect on the enzymes in addition to simple inhibition resulting from a blockade of cell division. The former possibility was examined by incubating mucosal homogenates with various concentrations of the alkaloid for 30 min. Subsequent measurement of the activities showed a significant depression when the alkaloid concentration was raised to 10 µg/mg wet mucosa. It is concluded that vinblastine sulfate not only arrests the mitosis of the crypts but influences, additionally, the enzymatic complements of the enterocytes.

Keywords:
Intestinal dipeptidases, Vinblastine sulfate
This content is only available via PDF.
© 1979 S. Karger AG, Basel
1979
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.